Gaudium IVF & Women Health Intrinsic Value
Gaudium IVF & Women Health intrinsic value. Gaudium IVF & Women Health (GAUDIUMIVF) median intrinsic value is ₹82.81 from 9 valuation models (range ₹34–₹142), vs current price ₹103.25 — -19.8% downside (Trading Above Median Value), margin of safety -24.7%. For current market price and key ratios, visit GAUDIUMIVF screener.
GAUDIUMIVF Valuation Methods Summary — DCF, Graham Number & P/E
Gaudium IVF & Women Health intrinsic value across 9 models vs current price ₹103.25 — upside/downside and value range per method. Read Gaudium IVF & Women Health dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹117.92 | ₹94.34 - ₹141.50 | +14.2% | EPS: ₹5.36, Sector P/E: 22x |
| Book Value Method | asset | ₹84.44 | ₹76.00 - ₹92.88 | -18.2% | Book Value/Share: ₹42.22, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹68.89 | ₹62.00 - ₹75.78 | -33.3% | Revenue/Share: ₹34.44, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹133.33 | ₹120.00 - ₹146.66 | +29.1% | EBITDA: ₹48.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹41.30 | ₹33.04 - ₹49.56 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹34.30 | ₹30.87 - ₹37.73 | -66.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹82.81 | ₹74.53 - ₹91.09 | -19.8% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹142.22 | ₹128.00 - ₹156.44 | +37.7% | ROE: 21.1%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹71.36 | ₹64.22 - ₹78.50 | -30.9% | EPS: ₹5.36, BVPS: ₹42.22 |
GAUDIUMIVF Intrinsic Value vs Market Price — All Valuation Models
Gaudium IVF & Women Health fair value range ₹34–₹142 vs current market price ₹103.25 across 9 valuation models. Compare with GAUDIUMIVF fair price to assess whether the stock is under or overvalued.
GAUDIUMIVF Intrinsic Value Analysis — Undervalued or Overvalued?
Gaudium IVF & Women Health median intrinsic value ₹82.81, current price ₹103.25 — Trading Above Median Value by 19.8%, margin of safety -24.7%.
What is the intrinsic value of GAUDIUMIVF?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gaudium IVF & Women Health (GAUDIUMIVF) is ₹82.81 (median value). With the current market price of ₹103.25, this represents a -19.8% variance from our estimated fair value.
The valuation range spans from ₹34.30 to ₹142.22, indicating ₹34.30 - ₹142.22.
Is GAUDIUMIVF undervalued or overvalued?
Based on our multi-method analysis, Gaudium IVF & Women Health (GAUDIUMIVF) appears to be trading above median value by approximately 19.8%.
GAUDIUMIVF Financial Health — Key Ratios vs Industry Benchmarks
Gaudium IVF & Women Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 36.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.1% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 40.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.64x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GAUDIUMIVF Cash Flow Quality — Operating & Free Cash Flow
Gaudium IVF & Women Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹9 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹3 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹24 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-1 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |